Amgen Inc. Stock News

The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can ke

Sponsored: Find a Qualified Financial Advisor Finding a qualified financial advisor doesn't have to be hard.

In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day.

There is always a constant search for dependable prospects that offer stability and advancement. In the middle of this hunt, dividend stocks with growth stand out as possible bright spots that give i

Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.

Dividend investing can be a profitable strategy for traders, providing an extra source of income alongside potential stock gains. Amgen (NASDAQ: AMGN) has demonstrated strong performance, surpassing t

Amgen, a leading U.S. biotech company, has outperformed the S&P 500 since 2011. However, the biotech's shares have struggled in 2024.

Delta Air Lines shares could finally take off this year once enough investors can shake off unmerited worries. Drugmaker Amgen's singles and doubles approach to the business makes more sense than alwa

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Planning Underway for Phase 3 Development of Tezepelumab in COPD   THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Pha

Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade hig

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen has a history of outperforming peers and the market due to its effective capital allocation in the pharmaceutical industry. AMGN is executing well with sales and volume growth, and has a robust

Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024, focu

The Investment Committee give you their top stocks to watch for the second half.